Vanda Pharmaceuticals (VNDA) - Due Diligence

hourglass

Loading…

Preparing the latest DD data, styles and content.

68OpportunityDD: Jul 04, 2026Analyst: 68

paidPrice at analysis date

USD 7.56 (04/07/2026)

domainMkt cap

$444M

pie_chartShares

58.8M

candlestick_chart52W

$3.81-$9.94

trending_downShort interest

11.4%

INFONASDAQSpecialty Pharma280 employeesFounded 2003

Verdict: Favorable Risk/Reward — Asymmetric setup, cash-backed floor

Beaten-down specialty pharma trading at EV/Sales 2026E ~0.9x — cheapest of comparable single-asset commercial peers. Multiple recent FDA approvals (BYSANTI July-1 launch, NEREUS May launch) are largely un-priced. Cash of $202M (46% of market cap) provides asset-based floor; imsidolimab PDUFA on Dec-12-2026 is a binary near-term catalyst. Bear case dominated by heavy operating cash burn (-$109M TTM) shortening the runway if BYSANTI and NEREUS ramps disappoint.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-07-04

Vanda Pharmaceuticals (VNDA)

Specialty Pharma · NASDAQ · Washington, DC

"Cheap on cash & sales, expensive on cash burn — asymmetric only if BYSANTI ramps."

Cash floor $3.44/sh EV/Sales 0.9x 2026E OCF -$109M TTM SI 11.4% float 4 approved drugs

Fin. strength

/20 pts

EBITDA/FCF

/15 pts

Debt/leverage

/15 pts

Stage/business

/15 pts

Catalysts

/10 pts

Reg. risk

/8 pts

Risk/reward

/7 pts

Management

/5 pts

Sector/macro

/3 pts

Compliance

/2 pts

💡 Fair Value estimate — EV/Sales forward (primary) + Cash-Floor NAV (secondary)

Fair value base case

USD 11.2

Range: USD 6.50-USD 16.0

Price at analysis date: USD 7.56 (04/07/2026)

Base upside/downside: +48%

Methodology: EV/Sales forward is the primary metric — VNDA is not yet profitable on an operating basis so EV/EBITDA is not meaningful. Peer multiples applied to individual product lines to preserve mix effects (declining vs ramping vs mature). Implicit multiple of 1.95x EV/Sales sits at the low end of peer range, reflecting cash burn and launch execution risk. Sensitivity: a ±1x shift in overall EV/Sales moves FV by ±$3.20/sh. ⚠️ Not investment advice.

Component	Assumption	USD/share
Enterprise value — Fanapt franchise	2.0x EV/Rev on Fanapt run-rate ~$115M FY26E (Q1'26 +26% YoY)	+3.90
Enterprise value — HETLIOZ + PONVORY	1.5x EV/Rev on ~$75M FY26E (mature/declining)	+1.90
NEREUS + BYSANTI new launches	3.0x EV/Rev on $50M combined FY26E (ramping)	+2.55
Net cash	($202M cash − $0 debt) / 58.8M sh, cash Q1'26 (30% haircut for burn to YE26)	+2.40
Imsidolimab option value (GPP)	40% prob × $75M NPV (rare disease, Dec-12 PDUFA) / 58.8M sh	+0.51
Dilution / cash burn reserve	−$4M discount for potential shelf if BYSANTI ramp slow	−0.06
FV base case	Exact sum of components above	≈ $11.20

Bull

$15.00–$18.00

Probability: 25%

BYSANTI hits $80M peak year-1, NEREUS DTC scales, imsidolimab approved Dec-12. Multiple expands to 3x EV/Sales as burn narrows. Analyst PT $14.13 clears.

Base

$10.00–$12.50

Probability: 45%

Guidance mid-range hit ($265M), BYSANTI slow ramp ($15M year-1). Imsidolimab approved but modest launch. Multiple re-rates modestly to 2x EV/Sales.

Bear

$4.50–$6.00

Probability: 30%

BYSANTI flops (formulary access issues), NEREUS DTC misses, imsidolimab CRL. Cash burn continues at $100M/y — need equity raise 2027. Multiple compresses toward net cash only.

Methodology: Methodology: EV/Sales forward is the primary metric — VNDA is not yet profitable on an operating basis so EV/EBITDA is not meaningful. Peer multiples applied to individual product lines to preserve mix effects (declining vs ramping vs mature). Implicit multiple of 1.95x EV/Sales sits at the low end of peer range, reflecting cash burn and launch execution risk. Sensitivity: a ±1x shift in overall EV/Sales moves FV by ±$3.20/sh. ⚠️ Not investment advice. Not investment advice.

check_circle

✅ Recent catalyst — BYSANTI launched July 1, 2026

Vanda began U.S. commercial availability of BYSANTI (milsaperidone) for bipolar I and schizophrenia on July 1, 2026, three days before this report. Together with NEREUS DTC launch (May 2026) and Fanapt LAI development, the company is executing on the largest launch pipeline in its history. 2026 revenue guidance raised to $240–$290M vs. $203M in 2025.

⚠️ Methodology note: VNDA is a specialty pharma with 4 approved products and 1 BLA under FDA review. Valuation combines EV/Sales forward peer multiple (primary) and cash-floor NAV (secondary/downside anchor). Report classified [DISLOCATION] under asymmetry screening — classification is a selection criterion only; the fair value below is derived independently from peer multiples and does not presuppose the asymmetric thesis.

📊 Capital Structure · Short Interest · Buyback & Dilution

🟡 Short Interest

11.4%

6.2M shares short on ~55M float. Up +10.7% recent period, +31.1% YoY. Days to cover: 5.8. Moderate bearish positioning — modest squeeze potential on BYSANTI ramp beat.

🟢 Share dilution (1Y)

+2.1%

From ~58.7M to ~60.1M shares. Cause: stock-based compensation only. No shelf drawdown reported. Insider donation of 25,836 shares by director on 2026-05-20 (charitable, non-market).

🔴 Buyback

No active repurchase program despite $202M cash. Priority: fund BYSANTI/NEREUS launches and imsidolimab pre-launch. Missed opportunity at current EV/Sales <1x.

Short Interest — context

VNDA — 11.4%

11.4%

Interpretation: 11.4% short interest is in the "moderate-high" band (>10%) — signals meaningful bearish view on execution but not distress. State Street disclosed 5.1% passive stake on 2026-05-12 (13G filing) — provides institutional buying floor. Insider selling absent in the ordinary sense; only a charitable donation of 25,836 shares by a director in May.

$Financial analysis — FY2025

Revenue TTM

$216.1M

Guidance FY26 $240-290M (+11-34% YoY)

Gross margin TTM

94.0%

Typical for specialty pharma — commercial products

Operating CF TTM

-$109.4M

Heavy launch spend — narrows runway to ~24 months

Cash & marketable

$202.3M

Q1'26 vs $263.8M at YE25 (−$61.5M in one quarter)

Item	FY2023	FY2024	FY2025	TTM Q1'26	Guidance FY26
Revenue ($M)	184.7	197.4	202.9	216.1	240-290
Gross margin %	90%	92%	93%	94%	~93-94%
Operating income ($M)	-51.7	-89.3	-134.5	-151.2	N/D — heavy launch
Net income ($M)	-33.9	-73.6	-204.2	-220.5	N/D
Cash EoP ($M)	359.4	325.6	263.8	202.3	~130-160E
Diluted EPS ($)	-0.60	-1.28	-3.50	-3.74	N/D

Note: Net loss FY25 includes ~$120M non-cash impairment on PONVORY intangibles. Cash burn accelerated in Q1'26 due to $10M milestone paid to Eli Lilly on NEREUS approval + BYSANTI pre-launch spend.

Quarterly dynamics — last 5 quarters
Metric	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue ($M)	47.2	50.5	52.6	52.6	60.4
Gross margin %	93%	93%	94%	94%	94%
Net loss ($M)	-21.4	-25.8	-31.5	-125.5	-37.8
End-of-period cash ($M)	340.1	318.9	293.2	263.8	202.3

Financial position and sustainability

Runway (months at Q1'26 burn)

~20-24 mo

Fanapt YoY growth (Q1'26)

+26%

Piotroski F-Score

2/9

account_tree

Business model — 4 commercial + 1 BLA pipeline

Multi-asset specialty pharma with rare disease + CNS focus

Vanda commercializes four FDA-approved drugs (HETLIOZ, Fanapt, PONVORY, NEREUS) and just launched a fifth (BYSANTI, July 1, 2026). The commercial base — historically Fanapt-dominated — is being repositioned around new-launch growth in motion sickness (NEREUS), bipolar/schizophrenia (BYSANTI), with imsidolimab (rare pustular psoriasis, PDUFA Dec-12-2026) adding rare-disease optionality. Business is DTC-forward for NEREUS (novel channel) and physician-detail-based for others. Fanapt remains the cash-flow generator (+26% YoY Q1'26).

Fanapt (iloperidone) ~$115-125M FY26E (~45% rev) 🟢 ramping Schizophrenia + bipolar I. +26% YoY growth Q1'26. LAI formulation under development for relapse-prevention. Main cash-flow engine and de-facto "moat". HETLIOZ (tasimelteon) ~$55-65M FY26E (~24% rev) 🟡 mature Non-24 Hour Sleep-Wake Disorder + Smith-Magenis Syndrome. Jet-lag sNDA received FDA non-approval letter — company disputing. Steady mature franchise. NEREUS (tradipitant) ~$20-35M FY26E (~10% rev) 🟢 new launch May 2026 Motion sickness — first new pharmacologic in 40+ years. DTC platform pioneering channel. Additional indications: gastroparesis, GLP-1 nausea in development. BYSANTI (milsaperidone) ~$15-30M FY26E (~7% rev) 🟢 launched Jul-1-2026 Bipolar I + schizophrenia. NCE bioequivalent to iloperidone; exclusivity through 2044. Adjunctive MDD Phase 3 ongoing. Q3'26 first full launch quarter — critical read. PONVORY (ponesimod) ~$15-20M FY26E (~6% rev) 🔴 declining Relapsing MS. Struggling franchise — took $120M impairment in FY25. Repositioning attempts in psoriasis, ulcerative colitis. Not the story. Imsidolimab (BLA pipeline) Pre-revenue — $50-100M peak potential 🟡 PDUFA Dec-12-2026 Anti-IL-36R mAb for generalized pustular psoriasis (rare disease). Phase 3 GEMINI-1/2 positive. Japan orphan designation Jun-2026. Binary catalyst.

gavel

Legal, regulatory and risk analysis

Cash burn / runway compression

High

OCF -$109M TTM. Cash dropped $61.5M in single quarter (Q1'26). At current burn runway is ~24 months. If BYSANTI/NEREUS launches disappoint, an equity raise 2027 becomes likely, diluting the asymmetric setup.

BYSANTI formulary access risk

High

New chemical entity in a heavily-genericized antipsychotic class. Payer coverage decisions in H2 2026 will make/break launch trajectory. Historical Vanda commercial execution has been mixed.

Imsidolimab PDUFA binary — Dec 12, 2026

Medium

Phase 3 data supportive but rare-disease reviews can surprise. A CRL would delete option value and set back Vanda's dermatology thesis. Positive decision de-risks the pipeline optics.

FDA history — HETLIOZ jet lag CRL, tradipitant hold

Medium

Vanda has a track record of public FDA disputes (jet-lag sNDA rejection, prior tradipitant clinical hold). Management-agency relationship is functional but adversarial — priced into multiple.

PONVORY impairment / capital allocation

Medium

$120M impairment on PONVORY intangibles in FY25 shows the Idorsia-Janssen acquisition value was overpaid. Governance question over capital allocation discipline.

Net cash of $202M vs $444M market cap

Positive

Cash is 46% of market cap; zero long-term debt. Provides hard downside anchor: even in a stressed liquidation scenario, cash and receivables underpin ~$3.50/share.

Fanapt franchise durability

Positive

Fanapt has been growing +26% YoY on volume, without pricing games. LAI formulation in development extends the franchise beyond 2028 IP cliff on oral form. Cash-flow anchor of the business.

BYSANTI exclusivity through 2044

Positive

As NCE, BYSANTI carries data exclusivity + patents to 2044 — a 17-year runway not reflected in current sub-1x EV/Sales. If launch works, terminal-value story alone justifies re-rating.

article

SWOT analysis

Strengths

+Cash-backed floor ($3.44/sh) + zero debt
+Four approved drugs, one launching (BYSANTI Jul-1)
+Fanapt +26% YoY — durable cash generator
+94% gross margin — pricing power intact
+Multi-decade exclusivity on new NCE (2044)

Weaknesses

−OCF -$109M TTM — burn accelerating
−Piotroski F-Score 2/9 — weak fundamentals score
−$120M PONVORY impairment — capital-allocation blemish
−No buyback despite deep valuation discount
−Historical commercial execution mixed

Opportunities

→BYSANTI + NEREUS + imsidolimab: 3 launches in 12 months
→EV/Sales 0.91x fw — 55%+ discount vs peers
→Fanapt LAI formulation extending franchise
→GLP-1 nausea indication for tradipitant (NEREUS)
→M&A target given cash + validated launches

Threats

!Payer denial of BYSANTI on antipsychotic class
!Imsidolimab CRL (Dec-12 PDUFA)
!FDA proposal to extend NDA reviews (impacts pipeline timing)
!Equity dilution 2027 if launches under-execute
!Short interest 11.4% — sentiment overhang

article

Summary by assessment area

🟡 Financial risk — Moderate

Cash 46% of market cap provides floor
Burn -$109M TTM shortens runway to ~24mo
Zero debt — no covenant risk

🔵 Business risk — Moderate

4 approved drugs, 3 launching or fresh-launch
Fanapt engine +26% YoY intact
Execution track record mixed historically

🟢 Valuation setup — Attractive

EV/Sales 0.91x fw vs peer median 4.05x
Base FV $11.20 = +48% upside; PT $14.13
Cash-floor anchor = asymmetric R/R

{ "verdict_label": {"it": "Giudizio: Risk/Reward Favorevole", "en": "Verdict: Favorable Risk/Reward"}, "verdict_text": {"it": "Specialty pharma con 4 farmaci approvati e 1 BLA in review. Trading a EV/Sales 0.9x fw, deep discount vs peer median 4x. Cassa $202M (46% market cap) come floor. Catalizzatori: BYSANTI appena lanciato, imsidolimab PDUFA 12-Dic-2026. Rischio principale = cash burn $109M annui.", "en": "Specialty pharma with 4 approved drugs and 1 BLA under review. Trading at EV/Sales 0.9x fw, deep discount vs peer median 4x. Cash of $202M (46% of market cap) provides floor. Catalysts: BYSANTI just launched, imsidolimab PDUFA Dec-12-2026. Main risk = cash burn of $109M/y."}, "bull_points": [ {"it": "EV/Sales 0.9x fw vs mediana peer 4.05x: sconto del 55-60%", "en": "EV/Sales 0.9x fw vs peer median 4.05x: 55-60% discount"}, {"it": "Tre lanci in 12 mesi (NEREUS maggio, BYSANTI luglio, imsidolimab dic PDUFA)", "en": "Three launches in 12 months (NEREUS May, BYSANTI July, imsidolimab Dec PDUFA)"}, {"it": "Cassa $202M = 46% market cap, zero debito, floor asset-based solido", "en": "$202M cash = 46% of market cap, zero debt, solid asset-backed floor"} ], "bear_points": [ {"it": "OCF -$109M TTM, cassa scesa di $61M in un trimestre solo", "en": "OCF -$109M TTM, cash dropped $61M in a single quarter"}, {"it": "Track record commerciale mediocre, PONVORY impairment $120M in FY25", "en": "Weak commercial track record, $120M PONVORY impairment in FY25"}, {"it": "Imsidolimab PDUFA Dec-12 e' binario: CRL azzera l'option value", "en": "Imsidolimab PDUFA Dec-12 is binary: a CRL erases the option value"} ], "risks": [ {"it": "Runway ~24 mesi al burn attuale: raise equity 2027 se lanci deludono", "en": "Runway ~24 months at current burn: equity raise 2027 if launches disappoint"}, {"it": "Accesso payer BYSANTI in classe antipsicotici genericati e' incertezza chiave", "en": "BYSANTI payer access in genericized antipsychotic class is the key uncertainty"}, {"it": "Short interest 11.4% del float: overhang di sentiment se catalizzatori mancano", "en": "Short interest 11.4% of float: sentiment overhang if catalysts miss"} ] }

Sources & Disclaimer

Sources: Vanda Pharmaceuticals SEC filings (10-Q Q1 2026, 8-K May-6-2026 guidance raise, 8-K BYSANTI approval, form 4 director donation May-20), Yahoo Finance quote page (close 2026-07-02 $7.56), StockTitan overview & filings, PRNewswire release BYSANTI July-1 launch, Seeking Alpha Vanda 2026 catalyst run, MarketBeat analyst PT (avg $14.13, updated 2026-06-20), StockAnalysis peer data, MacroTrends historicals. Market data — last verified close 2026-07-02: VNDA ~$7.56 (T-1, Friday 2026-07-03 closed for Independence Day observed), market cap ~$444M, 52W range $3.81–$9.94, ~58.8M shares outstanding. Short interest: 11.4% of float, 5.8 days to cover. Cash Q1'26: $202.3M, zero long-term debt. ⚠️ Not investment advice.